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2+ entry via Orai1 store-operated Ca2+ channels in the plasma
membrane is critical to cell function, and Orai1 loss causes severe
immunodeficiency and developmental defects.  The tetraspanins
are a superfamily of transmembrane proteins that interact with specific
‘partner proteins’ and regulate their trafficking and clustering.  The aim
of this study was to functionally characterize tetraspanin Tspan18.  We
show that Tspan18 is expressed by endothelial cells at several-fold high-
er levels than most other cell types analyzed. Tspan18-knockdown pri-
mary human umbilical vein endothelial cells have 55-70% decreased
Ca2+ mobilization upon stimulation with the inflammatory mediators
thrombin or histamine, similar to Orai1-knockdown.  Tspan18 interacts
with Orai1, and Orai1 cell surface localization is reduced by 70% in
Tspan18-knockdown endothelial cells.  Tspan18 overexpression in lym-
phocyte model cell lines induces 20-fold activation of Ca2+ -responsive
nuclear factor of activated T cell (NFAT) signaling, in an Orai1-dependent
manner. Tspan18-knockout mice are viable.  They lose on average 6-fold
more blood in a tail-bleed assay.  This is due to Tspan18 deficiency in
non-hematopoietic cells, as assessed using chimeric mice. Tspan18-
knockout mice have 60% reduced thrombus size in a deep vein throm-
bosis model, and 50% reduced platelet deposition in the microcircula-
tion following myocardial ischemia-reperfusion injury. Histamine- or
thrombin-induced von Willebrand factor release from endothelial cells is
reduced by 90% following Tspan18-knockdown, and histamine-induced
increase of plasma von Willebrand factor is reduced by 45% in Tspan18-
knockout mice.  These findings identify Tspan18 as a novel regulator of
endothelial cell Orai1/Ca2+ signaling and von Willebrand factor release in
response to inflammatory stimuli. 
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ABSTRACT
Introduction
The tetraspanins are a superfamily of proteins contain-
ing four transmembrane regions that interact with and
regulate the trafficking, lateral mobility and clustering of
specific ‘partner proteins’.  These include signaling recep-
tors, adhesion molecules and metalloproteinases.1-3
Recently, the first crystal structure of a tetraspanin,
CD81, demonstrated a cone-shaped structure with a
cholesterol-binding cavity within the transmembranes.4
Molecular dynamics simulations suggest that cholesterol
removal causes a dramatic conformational change,
whereby the main extracellular region swings upwards.4
This raises the possibility that tetraspanins function as
‘molecular switches’ to regulate partner protein function
via conformational change, and suggests that
tetraspanins are viable future drug targets.
Tetraspanin Tspan18 was previously studied in chick
embryos, in which it stabilizes expression of the
homophilic adhesion molecule cadherin 6B to maintain
adherens junctions between premigratory epithelial cra-
nial neural crest cells.5,6 Transcriptional Tspan18 down-
regulation is required for loss of cadherin 6B expression,
breakdown of epithelial junctions, and neural crest cell
migration.  However, Tspan18 knockdown has no major
effect on chick embryonic development.5,6  The function
of Tspan18 in humans or mice has still not been studied.
Store-operated Ca2+ entry (SOCE) through the plasma
membrane Ca2+ channel Orai1 is essential for the healthy
function of most cell types.7  Loss of SOCE results in
severe immunodeficiency that requires a bone marrow
transplant for survival.  Further symptoms include ecto-
dermal dysplasia and impaired development of skeletal
muscle.7  The process of SOCE is biphasic.  The first step
is initiated following the generation of the second mes-
senger inositol trisphosphate (IP3) from upstream tyro-
sine kinase or G protein-coupled receptor signaling.  IP3
induces the transient release of Ca2+ from endoplasmic
reticulum (ER) stores via IP3 receptor channels.8
Depletion of Ca2+ is detected by the ER-resident dimeric
Ca2+-sensor protein STIM1, which then undergoes a con-
formational change and interacts with Orai1 hexamers in
the plasma membrane.9,10 STIM1 binding induces Orai1
channel opening and clustering via a mechanism that is
not fully understood, allowing Ca2+ entry across the plas-
ma membrane.9,10 The resulting increase in intracellular
Ca2+ concentration is relatively large and sustained, suffi-
cient to activate a variety of signaling proteins, including
the widely-expressed nuclear factor of activated T-cell
(NFAT) transcription factors.8
Endothelial cells line all blood and lymphatic vessels
and play a central role in hemostasis and in thrombo-
inflammation, in which inflammatory cells contribute to
thrombosis.11,12 In the thrombo-inflammatory disease
deep vein thrombosis, blood flow stagnation induced by
prolonged immobility, for example, is the trigger for
endothelial cells to exocytose Weibel-Palade storage
bodies via a mechanism involving Ca2+ signaling.13,14  This
releases the multimeric glycoprotein von Willebrand fac-
tor (vWF) and the adhesion molecule P-selectin, which
recruit platelets and leukocytes, respectively. vWF-bound
platelets provide a pro-coagulant surface for activation of
clotting factors and thrombin generation, neutrophils
release neutrophil extracellular traps, and mast cells
release endothelial-activating substances.15-17 This series
of thrombo-inflammatory events leads to formation of a
blood clot which occludes the vein, and can cause death
by pulmonary thromboembolism.
The aim of this study was to determine the function of
tetraspanin Tspan18 in humans and mice. We found that
Tspan18 is highly expressed by endothelial cells, inter-
acts with Orai1, and is required for its cell surface expres-
sion and SOCE function.  As a consequence, Tspan18-
deficient endothelial cells have impaired Ca2+ mobiliza-
tion and release of vWF upon activation induced by
inflammatory mediators, and Tspan18-knockout mice
are protected from deep vein thrombosis and myocardial
ischemia-reperfusion injury, and have defective hemo-
stasis.
Methods
Ethics statement
Procedures in Birmingham were approved by the UK Home
Office according to the Animals (Scientific Procedures) Act
1986, and those in Würzburg by the district government of
Lower Frankonia (Bezirksregierung Unterfranken).
Mice
Tspan18-/- mice were generated by Genentech/Lexicon
Pharmaceuticals on a mixed genetic background of
129/SvEvBrd and C57BL/6J.18  They were purchased from the
Mutant Mouse Regional Resource Center and bred as heterozy-
gotes to generate litter-matched Tspan18-/- and Tspan18+/+ pairs.
Radiation fetal liver chimeric mice were generated as
described.19
Antibodies
Anti-epitope tag antibodies were mouse anti-Myc 9B11 and
rabbit anti-Myc 71D10 (Cell Signaling Technology), mouse
anti-FLAG M2 and rabbit anti-FLAG (Sigma).  Other antibodies
were mouse anti-human calnexin AF18 (Abcam), rat anti-
mouse CD16/32 (BioLegend), CD41 (eBioscience) and panen-
dothelial cell antigen MECA-32 (BD Pharmingen), mouse anti-
ERK1/2 and rabbit anti-phospho-ERK1/2 (Cell Signaling
Technology) and rabbit anti-human vWF (GE Healthcare).
Biotinylated isolectin GS-IB4 glycoprotein was from
ThermoFisher Scientific.
Expression constructs
The NFAT/AP1-luciferase transcriptional reporter construct
has been described previously.20,21 pEF6/Myc-His (mock) and
pEF6/Myc-His/lacZ were from Invitrogen.  N-terminal FLAG-
tagged tetraspanin constructs were generated in pEF6/Myc-His
as  described.22,23  pcDNA3.1 Myc-His-tagged human Orai1 and
MO70-FLAG-tagged human Orai1 E106Q were from
Addgene24 and the dominant-active calcineurin was as
described.25
Cell culture and transfections
Detailed information on cell cultures is provided in the Online
Supplementary Appendix. Wild-type and IP3 receptor-deficient
DT40 chicken B-cell lines,26 and Jurkat human T-cell line, were
transfected by electroporation.21 Human embryonic kidney
(HEK)-293T (HEK-293 cells expressing the large T-antigen of
simian virus 40) and the human HeLa epithelial cell line were
transfected using polyethylenimine (Sigma)27 and Lipofectamine
2000 (Invitrogen),28 respectively.  Human umbilical vein
endothelial cells (HUVEC)29 were transfected with 10 nM
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Silencer Select siRNA duplexes (Invitrogen) using
Lipofectamine RNAiMAX (Invitrogen).
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR) was
performed using TaqMan assays for Tspan18, Orai1, Orai2,
Orai3, 18S and GAPDH.30 Details are available in the Online
Supplementary Appendix.
Lentiviral transduction
Human umbilical vein endothelial cells were lentivirally trans-
duced with Orai1-Myc as described.31 Details are  available  in
the Online Supplementary Appendix.
Nuclear factor of activated T-cell/AP-1-luciferase 
transcriptional reporter assay
The NFAT/AP-1-luciferase assay, and β-galactosidase assay to
normalize for transfection efficiency, were as described.21
Co-immunoprecipitation
A detailed description of co-immunoprecipitation from trans-
fected HEK-293T cell lysates22 is provided in the Online
Supplementary Appendix.
Immunofluorescence microscopy
Detailed information is provided in the Online Supplementary
Appendix. In brief, cells were prepared as described29 and the
Manders’ coefficients (M1 and M2) were used as the 
co-localization measure.32 Ear vasculature was imaged and quan-
tified as described.33,34
Immunohistochemistry
Immunohistochemistry was as described;35 details are avail-
able in the Online Supplementary Appendix.
Intracellular Ca2+
Human umbilical vein endothelial cells  were loaded with
Fluo-4 NW dye according to the manufacturer’s instructions
(Molecular Probes).  Fluorescence was measured every 3 seconds
for 5 minutes using a FlexStation fluorescence reader (Molecular
Devices), and thrombin (1 U/mL), histamine (20 μM) or iono-
mycin (10 μM) were injected after acquiring a baseline for 30
seconds.
ELISA and coagulation time assays
Detailed information is provided in the Online Supplementary
Appendix.
Platelet aggregation and adhesion to human umbilical
vein endothelial cells 
Platelet assays were as described;36,37 detailed information is 
provided in the Online Supplementary Appendix.
In vivo assays
Mouse models were as described;13,37-39 detailed information is
in the Online Supplementary Appendix.
Results
Tspan18 is expressed by endothelial cells
A lack of effective antibodies to many tetraspanins is a
current problem in the tetraspanin field.  This may be due
to their relatively small size, high degree of sequence con-
servation during evolution, and compact 4-transmem-
brane structure.4 For example, no Tspan18 antibodies
have been published, and commercially-available anti-
bodies are made to Tspan18 peptides and do not detect
full-length Tspan18 when rigorously tested (MG
Tomlinson, 2019, unpublished manuscript). Therefore, to
characterize the Tspan18 expression profile, mouse tis-
sues were tested by qPCR. Tspan18 mRNA was most
highly expressed in lung and at lower levels in other tis-
sues (Figure 1A).  Analyses of published transcriptomic
data40 showed that Tspan18 was most highly expressed
by endothelial cells compared to other mouse lung cell
types (Figure 1B).  Similar analyses of transcriptomic data
from mouse brain41 also showed relatively strong
endothelial expression of Tspan18 (Figure 1C).
Consistent with this, qPCR showed that Tspan18 was
expressed by primary HUVEC and the human microvas-
cular endothelial HMEC-1 cell line (Figure 1D).  Tspan18
expression was low or absent on most other cell types
tested, although peripheral blood leukocytes expressed
comparable levels to HUVEC (Figure 1D).  In transcrip-
tomic data from the Human Protein Atlas (www.proteinat-
las.org), Tspan18 was expressed by most human tissues at
a level between 10 and 70 tags per million, but in cell lines
was only expressed at 10 or greater tags per million by
HUVEC and 8 of the other 64 cell types analyzed.42
Tspan18 is required for Ca2+ signaling in primary
human endothelial cells
To investigate Tspan18 function, its expression in
HUVEC, which is a widely-used primary human
endothelial cell model, was knocked-down using two dif-
ferent siRNA duplexes.  Subsequent analyses revealed a
60% reduction in peak Ca2+ elevation in response to the
inflammatory mediator thrombin (Figure 2A).  A similar
defect was observed in response to histamine (Figure 2B).
Positive control ionomycin treatment gave a sustained
intracellular Ca2+ response in all samples (Figure 2C) and
effective knockdown was confirmed by qPCR (Figure
2D).  Functionality of thrombin and histamine receptors
was confirmed by anti-phospho-ERK1/2 mitogen-activat-
ed protein kinase (MAPK) western blotting, as this was
not affected by Tspan18 knockdown (Figure 2E).
Tspan18 promotes Ca2+-responsive nuclear factor of
activated T-cell signaling in lymphocyte cell lines
To investigate the mechanism by which Tspan18 regu-
lates Ca2+ signaling, a more tractable cell line system was
established, namely DT40 cells that are derived from
chicken B cells.  In this cell line, a transfected
NFAT/adapter protein 1 (AP-1) transcriptional luciferase
reporter can be used as a readout for Ca2+ signaling down-
stream of transfected membrane proteins.21,43
Transfection of a FLAG epitope-tagged Tspan18 expres-
sion construct was sufficient to induce robust NFAT/AP-1
activation (Figure 3A).  As controls, five other FLAG-
tagged tetraspanins (CD9, CD63, CD151, Tspan32 and
Tspan9) were chosen because they represent a diverse
range of tetraspanins based on sequence identities.22
These did not induce NFAT/AP-1 activation, despite their
substantially higher expression than Tspan18 as assessed
by anti-FLAG western blotting (Figure 3A).
Despite the fact that the NFAT/AP-1 promoter can be
activated by Ca2+ signaling, it is maximally activated by
combined Ca2+ signaling and MAPK; Ca2+ activates NFAT
and MAPK activates AP-1.  To determine whether
P.J. Noy et al.
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Tspan18 activates Ca2+ signaling, MAPK or both,
Tspan18-transfected DT40 cells were stimulated with the
Ca2+ ionophore ionomycin or phorbol ester PMA to acti-
vate the MAPK pathway.  PMA synergized with Tspan18
expression in activating NFAT/AP-1, but ionomycin  did
not (Figure 3B).  As a positive control, combined PMA and
ionomycin induced relatively strong NFAT/AP-1 activa-
tion in the presence or absence of Tspan18 (Figure 3B).
The capacity of Tspan18 overexpression to induce
NFAT/AP-1 activation was not restricted to DT40 B cells,
since similar data were obtained in the human Jurkat T-
cell line (Figure 3C).  Taken together, these data suggest
that Tspan18 promotes Ca2+ signaling and NFAT activa-
tion via a mechanism that is common to endothelial cells,
B cells and T cells.
Tspan18-induced nuclear factor of activated T-cell
activation requires functional Orai1 store-operated
Ca2+ entry channels
To understand the mechanism by which Tspan18 pro-
motes Ca2+ signaling, a series of NFAT/AP-1 reporter
experiments were conducted in gene-knockout DT40
cells and using inhibitors and a dominant-interfering con-
struct.  Firstly, Tspan18-induced NFAT/AP-1 activation
was found to be independent of the three IP3 receptors
(Figure 3D).  IP3 receptors release Ca2+ from ER stores in
response to tyrosine kinase and G protein-coupled recep-
tor activation, suggesting that Tspan18 does not operate
on these pathways or IP3 receptors themselves. However,
Tspan18 did not activate NFAT/AP-1 following chelation
of extracellular Ca2+ (Figure 3E), or following treatment
with the immunosuppressive drug cyclosporin A (Figure
3F), which prevents NFAT translocation to the nucleus by
inhibiting its activatory phosphatase calcineurin.  These
data suggest that Tspan18 might induce Ca2+ entry via the
SOCE channel Orai1, a major entry route for extracellular
Ca2+ in non-excitable cells.8 Consistent with this possibil-
ity, a dominant interfering form of Orai1 (E106Q), which
multimerizes with endogenous Orai1 to yield a non-func-
tional channel,44-46 inhibited Tspan18-induced NFAT/AP-1
activation (Figure 3G). As a positive control to confirm
that downstream NFAT signaling was still intact in the
presence of dominant interfering Orai1, its inhibitory
effect was overcome by the expression of an active form
of calcineurin (Figure 3G). Therefore, Tspan18 may acti-
vate Ca2+ entry through the Orai1 SOCE pathway.
Tspan18 interacts with Orai1
To investigate whether Tspan18 interacts with Orai1,
transfected epitope-tagged proteins were used because of
Tspan18 regulates Orai1 in endothelial cells
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Figure 1.  Tspan18 is highly expressed by endothelial cells. (A) Quantitative real-time polymerase chain reaction (qPCR) was carried out for Tspan18 using cDNA
derived from a panel of mouse tissues.  Data were normalized for the HPRT housekeeping gene and adjusted such that the lung value was 100 in each experiment.
Error bars represent Standard Error of Mean from three independent tissue samples.  (B) RNA-Seq data from major cell types in mouse lung, generated by Du et
al.,40 was used to show Tspan18 mRNA expression levels as fragments per kilobase of transcript sequence per million mapped fragments (FPKM). (C) RNA-Seq data
from major cell types in mouse brain, generated by Zhang et al.,41 was used to show Tspan18 mRNA expression levels as described in (B).  (D) qPCR was carried out
for Tspan18 on cDNA derived from a panel of primary human cells [dermal fibroblasts, aortic smooth muscle, hepatocytes, peripheral blood leukocytes from buffy
coat and human umbilical vein endothelial cells (HUVEC)], and human cell lines (HEK-293T human embryonic kidney cells, MDA-MB-231 epithelial cells, DAMI
megakaryocytic cells, HEL and K562 erythroleukemia cells, U937 monocytic cells, Jurkat and HPB-ALL T cells, DG75 and Raji B cells and HMEC-1 microvascular
endothelial cells). Data were normalized for actin and adjusted such that the HUVEC value was 100 in each experiment.  Error bars represent Standard Error of Mean
from two independent cell samples.  
A B
C D
the lack of effective antibodies to Tspan18. To test for an
interaction using co-immunoprecipitation, transfected
HEK-293T cells were lyzed in 1% digitonin, a stringent
detergent that has been used previously to identify
tetraspanin-partner protein interactions.22,47 FLAG-tagged
Tspan18 co-immunoprecipitated with Myc-tagged Orai1,
but five other control tetraspanins did not (Figure 4A).
Moreover, Tspan18 and Orai1 co-localized when
expressed in HeLa cells, at a level of approximately 90%
pixel co-localization when assessed using the Manders’
coefficient (Figure 4B). These data suggest that Tspan18
interacts with Orai1.
P.J. Noy et al.
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Figure 2. Tspan18-knockdown endothelial cells have impaired Ca2+ mobilization. (A-D) Human umbilical vein endothelial cells (HUVEC) were transfected with a neg-
ative control siRNA (CON) or with one of two independent siRNA targeting Tspan18 (T18 KD).  After 48 hours, HUVEC were loaded with the Ca2+-sensitive dye Fluo-4
NW and Ca2+ measurements taken using a FlexStation fluorescence reader during addition (arrow) of (A) 1 U/mL thrombin, (B) 20 μM histamine, or (C) 10 μM iono-
mycin.  Representative Ca2+ traces are shown for Tspan18-knockdown HUVEC (left), with quantitation of maximum intracellular Ca2+ concentrations (right).  Data were
analyzed by one-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent the Standard Error of Mean (SEM) from three independent experiments.
*P<0.05; ***P<0.001. (D) siRNA-transfected HUVEC from (A) to (C) were harvested, mRNA extracted, cDNA produced and Tspan18 mRNA levels were assessed by
quantitative real-time polymerase chain reaction (qPCR). Data were normalized to 18S and actin as internal controls and adjusted such that the non-siRNA-trans-
fected mock value was 1 in each experiment. Data were then normalized by logarithmic transformation, and analyzed by one-way ANOVA and Tukey’s multiple com-
parison test. Error bars represent the Standard Error of the Mean from three independent experiments. ***P<0.001. (E) HUVEC were subjected to Tspan18 siRNA
knockdown as described for (A-D), stimulated with 1 U/mL thrombin or 20 μM histamine for 5 minutes, then whole cell lysates were analyzed by western blotting
with phospho-ERK1/2 and total ERK1/2 antibodies.  (Left) Representative blots. (Right) Quantitation of three independent experiments.  Error bars represent SEM.
Knockdown efficiency was similar to that shown in (D) (data not shown). secs: seconds; RFU: relative fluorescence unit.
A
B
C D
E
Orai1-knockdown endothelial cells have impaired Ca2+
mobilization and Orai1 surface expression requires
Tspan18
To determine whether knockdown of Orai1 could phe-
nocopy Tspan18 knockdown, intracellular Ca2+ mobiliza-
tion was measured following siRNA-mediated knock-
down of Orai1.  This resulted in impaired Ca2+ mobiliza-
tion in response to thrombin (Figure 5A) or histamine
(Figure 5B).  As a control, knockdown of the other Orai
family members, Orai2 and Orai3, did not affect Ca2+
mobilization (Figure 5A and B), in agreement with previ-
ous studies on Orai proteins in HUVEC.48,49 Positive con-
trol ionomycin treatment gave a sustained intracellular
Ca2+ response in all samples (Figure 5C) and effective
knockdown was confirmed by qPCR (Figure 5D-F).
A common mechanism of tetraspanin function is to
regulate their partner proteins by facilitating their exit
from the endoplasmic reticulum (ER) and trafficking to
the cell surface.1,50,51 To determine whether Orai1 localiza-
tion could be regulated by Tspan18 in this manner,
HUVEC were lentivirally transduced with Myc-Orai1 and
transfected with control or Tspan18 siRNA duplexes, and
Orai1 subcellular localization assessed by confocal
microscopy.  Orai1 was localized primarily to the cell
periphery in control cells, but this was reduced following
Tspan18 knockdown, with Orai1 partially co-localized
with the ER marker calnexin (Figure 5G). Quantitative
analyses showed that approximately 40% of Orai1 was
Tspan18 regulates Orai1 in endothelial cells
haematologica | 2019; 104(9) 1897
Figure 3.  Tspan18 overexpression in cell lines activates Ca2+-responsive NFAT signaling in an Orai1-dependant manner. (A) The DT40 B cell line was transfected
with an NFAT/AP-1-luciferase reporter construct, a β-galactosidase expression construct driven by the elongation factor (EF)-1a promoter to control for transfection
efficiency, and FLAG-tagged mouse tetraspanin constructs or empty vector control.  At 24 hours (h) post transfection, cells were lyzed and assayed for luciferase and
β-galactosidase. Luciferase data were normalized for β-galactosidase values (left).  Whole cell lysates from these cells were separated by SDS-PAGE and blotted with
an anti-FLAG antibody. (Right) Representative blot. (B and C) The DT40 B cell line (B) and the human Jurkat T cell line (C) were transfected with an NFAT/AP-1-
luciferase reporter construct and β-galactosidase expression construct with (+) or without (-) FLAG-tagged mouse Tspan18.  At 24 h post transfection cells were stim-
ulated for 6 h with 50 ng/mL PMA or 1 μM ionomycin (Iono) (left), or both together (right).  Luciferase assays were then performed as described in (A). (D) DT40 cells
with (+) or without (-) expression of FLAG-tagged mouse Tspan18 were tested for NFAT/AP-1 luciferase activity as described in (A), but using cells with gene knockouts
of the three IP3 receptors (IP3R-) in comparison to wild-type (WT) cells (left).  Whole cell lysates were western blotted with an anti-FLAG antibody (right).  (E and F)
DT40 cells with (+) or without (-) expression of FLAG-tagged mouse Tspan18 were tested for NFAT/AP-1 luciferase activity as described in (A), except that cells were
treated with 4 mM EGTA as a Ca2+ chelator (E) or with 2 μM cyclosporin A as a calcineurin inhibitor (F).  (G) DT40 cells were transfected with FLAG-tagged human
Tspan18 in the presence or absence of a dominant negative human Orai1 E106Q mutant construct, or a consitutively active human calcineurin construct.  The exper-
iment was conducted as described for (A).  All luciferase data were corrected for β-galactosidase values, normalized by logarithmic transformation, and analyzed by
one-way ANOVA and Tukey’s multiple comparison test. *P<0.05; **P<0.01; ***P<0.001.  Error bars represent the Standard Error of the Mean from at least three
independent experiments. ns: not significant.
A B
C D
E F G
ER-localized in Tspan18 knockdown cells compared to
10-15% in control cells.  This partial co-localization could
be due to some Orai1 localization in the Golgi and/or
trans-Golgi network, as shown by staining close to the
nucleus, rather than the more extended perinuclear retic-
ular staining of the ER (Figure 5G).  These data support a
role for Tspan18 in regulating Orai1 exit from the ER,
and/or Golgi, and trafficking to the cell surface.
Tspan18 deficient mice have impaired hemostasis due
to a defect in non-hematopoietic cells
To investigate Tspan18 function in vivo, Tspan18-
knockout mice were acquired from Genentech/Lexicon
Pharmaceuticals.  These mice had been generated as part
of a library of 472 knockouts,18 but were functionally
uncharacterized.  Breeding of heterozygotes gave an
equal proportion of male and female mice with
Mendelian genotype ratios, and the mice bred successful-
ly as homozygote knockouts (data not shown).
Furthermore, Tspan18-knockout mice had normal body
weights and whole blood cell counts (data not shown).
Tspan18-knockout mice were first evaluated for a
hemostasis phenotype using a tail bleed assay. Most
Tspan18-knockout mice bled more than wild-type litter-
mates, demonstrating a significant disruption to hemosta-
sis (Figure 6A). Some Tspan18-knockout mice did not
bleed excessively (Figure 6A), indicating that the bleeding
phenotype was variable. This variability could be due to
genetic modifier loci, as demonstrated in mice deficient
for the platelet collagen/fibrin receptor GPVI.52 To deter-
mine whether impaired hemostasis was due to loss of
Tspan18 from hematopoietic or non-hematopoietic cells,
tail bleeding assays were performed on irradiated fetal
liver chimeric mice. These demonstrated that the bleed-
ing phenotype was due to Tspan18 loss from non-
hematopoietic cells (Figure 6A), and suggests that a
platelet defect is not responsible. Consistent with this,
Tspan18-knockout platelets aggregated normally in
response to collagen (Figure 6B) or thrombin (Figure 6C).
Furthermore, prothrombin time and activated partial
thromboplastin time tests showed that coagulation was
similar for wild-type and Tspan18-knockout plasma
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Figure 4.  Tspan18 interacts with Orai1. (A)
HEK-293T cells were transfected with a Myc-
tagged human Orai1 expression construct and
one of a panel of FLAG-tagged human
tetraspanin constructs. Cells were lyzed in 1%
digitonin and immunoprecipitated with an
anti-FLAG antibody.  Samples were separated
by SDS-PAGE and both immunoprecipitated
(IP) and whole cell lysate (WCL) samples were
blotted with anti-FLAG and anti-Myc antibod-
ies.  A representative blot for each is shown
(left) with quantitation of Myc-tagged Orai1
immunoprecipitated with the tetraspanins
(right). Data were nomalized by logarithmic
transformation before analysis by one-way
ANOVA and Dunnett’s post test. Error bars rep-
resent Standard Error of Mean (SEM) from
three independent experiments. *P<0.05. (B)
HeLa cells were transfected with Myc-tagged
human Orai1, FLAG-tagged human Tspan18,
or both constructs.  Cells were fixed and
stained with an anti-Myc antibody (green), an
anti-FLAG antibody (red), and imaged by confo-
cal microscopy (left).  The Manders' coeffi-
cients (M1 and M2) were calculated from the
confocal stacks to quantify the degree of over-
lap (right). Error bars represent the SEM from
three independent experiments. 
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(Figure 6D and E). These data suggest that the impaired
hemostasis phenotype is due to a defect in a non-
hematopoietic vascular cell type such as the endothelial
cell.  This did not appear to be due to any observable
structural defects in the vasculature, because immunohis-
tochemistry analyses of blood vessels in organs such as
kidney and pancreas were similar for wild-type and
Tspan18-knockout mice (Figure 6F), as were immunoflu-
orescence analyses of blood vessels in the ear (Figure 6G).
Tspan18 and Orai1 are required for endothelial
release of von Willebrand factor in response to 
inflammatory mediators
Endothelial cell stimulation by inflammatory agonists
induces vWF release from Weibel-Palade bodies via a
process that involves Ca2+ signaling.14 To investigate
whether Tspan18 could be required for vWF release,
HUVEC were subjected to Tspan18 knockdown and
stimulated in culture medium with thrombin or hista-
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Figure 5.  Orai1-knockdown endothelial cells have impaired Ca2+ mobilization and Orai1 surface expression requires Tspan18. (A-F) Human umbilical vein endothe-
lial cells (HUVEC) were transfected with a negative control siRNA (CON) or with one of two independent siRNA targeting Orai1, Orai2 or Orai3 (Orai1-3 KD).  After 48
hours (h), Ca2+ measurements were taken as described in Figure 2A-C, following addition of 1 U/mL thrombin (A), 20 μM histamine (B), or 10 μM ionomycin (C), and
quantitation of maximum intracellular Ca2+ concentrations is shown. Error bars represent Standard Error of the Mean (SEM) from three independent experiments.
**P<0.01; ***P<0.001.  (D-F) siRNA-transfected HUVEC from (A-C) were subjected to quantitative real-time polymerase chain reaction (qPCR) for Orai1 (D), Orai2
(E) or Orai3 (F), as described for Figure 2D. Error bars represent SEM from three independent experiments. ***P<0.001.  (G) HUVEC lentivirally-transduced to
express Myc-tagged Orai1 were treated with control or Tspan18 siRNA.  Cells were stained with anti-Myc (white) or anti-calnexin endoplasmic reticulum marker (red)
antibodies, and representative confocal microscopy images are shown (top).  In the line graphs below the images (bottom), the percentage expression of Orai1 (black)
and calnexin (red) across the yellow line in the top panel was determined using ImageJ. The percentage of Orai1 that localized to a calnexin endoplasmic reticulum
mask was then quantified (right).  Data were generated from 15 cells per condition from three independent experiments (five cells per condition per experiment).
Error bars represent SEM. ***P<0.001. RFU: relative fluorescence unit.
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mine.  Soluble vWF release, as detected by ELISA, was
reduced by approximately 90% compared to control cells
(Figure 7A).  This was corroborated by immunofluores-
cent staining of vWF that showed minimal release of
Weibel-Palade bodies after Tspan18 knockdown (Figure
7B).  Similar to Tspan18, Orai1 knockdown reduced
Weibel-Palade body release after thrombin stimulation,
but knockdown of Orai2 or Orai3 had no effect (Figure
7C).  Furthermore, Tspan18 knockdown reduced platelet
adhesion to a thrombin-activated HUVEC monolayer by
85-90% (Figure 7D).  These data support a role for
Tspan18 and Orai1 in vWF release and platelet capture
following endothelial cell activation by inflammatory
mediators.
P.J. Noy et al.
1900 haematologica | 2019; 104(9)
Figure 6. Tspan18-knockout mice have a hemostasis defect due to the absence of Tspan18 expression by non-hematopoietic cells. (A) Tail bleeding assays were
performed by amputating 3 mm tail tips of anesthetized mice and the weight of blood lost was measured.  The mice were Tspan18+/+, Tspan18-/-, or lethally irradiated
Tspan18-/- or Tspan18+/+ mice reconstituted with fetal liver cells from Tspan18+/+ or Tspan18-/- embryos.  Each symbol represents one animal.  All data were analyzed
by Fisher’s exact test. *P<0.05;  ***P<0.001.  Note that bleeding was stopped by cauterizing the tails of some mice, because of regulations limiting the amount of
blood loss on our Home Office License. (B and C) Washed platelets from Tspan18+/+ or Tspan18-/- mice were activated with 3 μg/mL collagen (B) or 0.3 U/mL thrombin
(C), and aggregation was measured by light transmission with stirring.  Quantitated percentage aggregation each minute is shown.  Error bars represent the Standard
Error of  Mean (SEM) from at least three pairs of litter-matched mice.  (D and E) Plasma samples from Tspan18+/+ and Tspan18-/- mice were subjected to a prothrombin
time test with human placental thromboplastin (D) and an activated partial thromboplastin time test with purified soy phosphatides with ellagic acid (E). Error bars
represent SEM from four pairs of litter-matched mice. (F) Immunohistochemistry was used to show a grossly normal vasculature in Tspan18+/+ and Tspan18-/- mice
formalin-fixed paraffin-embedded 5 μm sections from kidney and pancreas, using the MECA32 anti-mouse panendothelial cell antibody. Images are representative
of three pairs of litter-matched mice. (G) Confocal microscopy was used to show a grossly normal vasculature in Tspan18+/+ and Tspan18-/- mice ears, by staining ante-
rior ear tissue with biotinylated isolectin GS-IB4 glycoprotein followed by Alexa647-conjugated streptavidin. Images are representative of three pairs of litter-matched
mice.  ImageJ quantitation of 3 fields of view (500 x 500 pixels) per mouse showed a mean total vessel length of 11131±1271 pixels for Tspan18+/+ and 11684±283
pixels for Tspan18-/- (n=3; error represents SEM). mins: minutes.
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Figure 7. Tspan18-knockdown endothelial cells have impaired histamine- and thrombin-induced release of von Willebrand Factor (vWF).  (A) Human umbilical vein
endothelial cells (HUVEC) were transfected with a negative control siRNA (CON) or with one of two independent siRNA targeting Tspan18 (T18 KD). After 48 hours,
HUVEC were stimulated with 1 U/mL thrombin or 20 μM histamine for 5 minutes (min).  Cultured media was removed and assayed for vWF by ELISA.  Pre-stimulation
levels of vWF were subtracted from these data.  Error bars represent the Standard Error of Mean (SEM) from three experiments. **P<0.01.  (B) HUVEC transfected
as described in (A) were stimulated with 1 U/mL thrombin for 5 min, and the cells were fixed and stained with an anti-vWF antibody followed by Alexa488-conjugated
secondary antibody.  Representative confocal microscopy images are shown (left).  Z-stack images were de-noised, background-subtracted and analyzed for the num-
ber of vWF cellular bodies, using ImageJ.  Counts were made on 5-10 cells per experiment for four independent experiments (right panel).  Error bars represent
Standard Error of Mean (SEM). ***P<0.001; ns: not significant.  (C) The experiment and quantitation was conducted as for (B), except that HUVEC were mock-trans-
fected with no siRNA (Mock), transfected with negative control siRNA (CON), or siRNA to Orai1, Orai2 or Orai3 (KD).  (D) HUVEC were siRNA-transfected and stimulated
with 1 U/mL thrombin for 5 min as described in (A).  Human washed platelets were fluorescently labeled and incubated with the HUVEC monolayers. Non-adherent
platelets were removed by washing and images were collected.  Representative fluorescent images of adhered platelets (top) and phase contrast images of the
HUVEC monolayers and adhered platelets (bottom) are shown, with quantitation of platelet adhesion from three independent experiments (right). Error bars represent
SEM. *P<0.05.  
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Figure 8. Tspan18-knockout mice have impaired histamine-
induced von Willebrand Factor (vWF) release and impaired
thrombo-inflammatory responses. (A) Tspan18+/+ and
Tspan18-/- mice were intraperitoneally-injected with hista-
mine and plasma vWF levels were measured 30 minutes
(min) later by ELISA.  Error bars represent Standard Error of
Mean (SEM) from eight Tspan18+/+ and seven Tspan18-/-
mice. *P<0.05.  (B) Tspan18+/+and Tspan18-/- mice were
anesthetized, and the abdominal aorta exposed and
mechanically injured through a single firm compression with
forceps.  Blood flow was subsequently monitored with a
Doppler flowmeter to calculate the time until complete occlu-
sion of the vessel.  Each symbol represents one animal.  (C)
Tspan18+/+ and Tspan18-/- mice were anesthetized and the
mesentery was exteriorized through an abdominal incision.
Platelets were fluorescently labeled with Dylight 488-conju-
gated anti-GPIX derivative.  Small mesenteric arterioles were
exposed to FeCl3-induced chemical injury via topical applica-
tion.  Time to appearance of the first thrombi was recorded
(left), and the time until complete occlusion of the vessel
was measured using fluorescence intravital microscopy
(right).  Each symbol represents one animal.  (D) Tspan18+/+
and Tspan18-/- mice were anesthetized and surgery per-
formed to stenose the inferior vena cava.  After 48 hours (h),
thrombus length (left) and weight (right) were measured.
Each symbol represents one animal and horizontal bars rep-
resent the median. *P<0.05.  All data in (A-D) were analyzed
by one-way ANOVA with Dunnett’s multiple comparisons test.
(E) Myocardial ischemia-reperfusion injury was induced in
the left ventricle of the beating heart of anesthetized mice by
occluding the left anterior descending artery for 45 min with
a suture.  Reperfusion was instigated for 2 h by removal of
the ligature, after which the organ was harvested.  Frozen
sections were analyzed for the presence of platelets in the
microcirculation by immunofluorescence microscopy.  Three
litter-matched pairs of Tspan18+/+ and Tspan18-/- mice were
used, with three sections per mouse and five images ana-
lyzed per section.  Each symbol represents one image.  For
each image, the integrated density value was calculated as
a representation of the total number of platelets (left), and
the average aggregate size was also calculated (right).  Error
bars represent the SEM and data were analyzed by Mann-
Whitney test. ****P<0.0001. 
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Tspan18-knockout mice have impaired 
histamine-induced release of endothelial von
Willebrand factor and impaired thrombo-inflammatory
responses
To determine whether Tspan18 has a role in vWF
release in vivo, Tspan18-knockout mice were intra-peri-
toneally injected with histamine, and plasma vWF levels
were analyzed by ELISA. Induced plasma vWF release
was reduced by approximately 50% in the absence of
Tspan18 (Figure 8A). Basal plasma vWF was normal in
Tspan18-knockout mice (Figure 8A), indicating a require-
ment for Tspan18 in regulated, but not basal, vWF release.
To investigate the role of Tspan18 in thrombosis, two
arterial thrombosis models and two thrombo-inflammato-
ry models were used. In a platelet-driven aorta injury arte-
rial thrombosis model,38 no difference in time to complete
occlusion of the vessel between Tspan18-knockout and
wild-type littermate control mice was observed (Figure
8B). Similarly, there was no thrombosis defect in mesen-
teric arterioles following application of FeCl3 (Figure 8C),
which is also a platelet-driven model,38 but shows reduced
platelet deposition and thrombus formation in the com-
plete absence of vWF.53,54 In a deep vein thrombosis throm-
bo-inflammatory model that is dependent on endothelial
vWF,13 thrombus length and weight were reduced by
approximately 60% in the Tspan18-knockout mice, com-
pared to wild-type littermate controls (Figure 8D).
Moreover, 4 of 9 Tspan18-knockout mice failed to develop
a thrombus compared to 100% thrombus formation in
wild-type mice (Figure 8D). Macroscopically, thrombi from
Tspan18-knockout mice had similar red and white parts to
those from wild-type mice (data not shown).  Finally, in a
vWF-dependent myocardial ischemia-reperfusion throm-
bo-inflammatory model,55,56 platelet deposition and aggre-
gate size in the microcirculation were reduced by approxi-
mately 50% (Figure 8E).  The reduction in severity in the
two thrombo-inflammatory models is consistent with the
requirement of Tspan18 for endothelial vWF release in
response to inflammatory mediators.
Discussion
We have discovered that Tspan18 is expressed by
endothelial cells and interacts with the SOCE channel
Orai1.  Tspan18-knockdown endothelial cells had
reduced Orai1 expression at the cell surface and impaired
Ca2+ signaling. This is consistent with the established role
of tetraspanins in interacting with specific partner pro-
teins in the ER, and promoting their trafficking to the cell
surface,1,50,51 albeit via mechanisms that are yet to be
defined.  Tspan18 is not particularly related to any of the
other 32 mammalian tetraspanins,22 suggesting that it may
be unique amongst tetraspanins in regulating Orai1.
Indeed, none of the five tetraspanins that were selected as
controls interacted with Orai1, or induced Ca2+-respon-
sive NFAT activation, when over-expressed.
At the cell surface, tetraspanins can regulate the lateral
diffusion and clustering of their partner proteins.2,3 A
question that arises from the present study is whether
Tspan18 regulates Orai1 clustering at the endothelial cell
surface.  Interestingly, a unimolecular coupling model of
Orai1 activation was recently proposed, whereby one
molecule of a STIM1 dimer is sufficient to induce opening
of the Orai1 hexamer channel.10  This would enable the
other STIM1 molecule in the dimer to cross-link with a
second Orai1 hexamer and form a lattice of clustered
Orai1 channels.  The degree of cluster formation could
dictate the kinetics of channel activation and could con-
centrate Ca2+ influx to particular regions of the plasma
membrane.10 This could affect the extent to which down-
stream effectors are activated. Tetraspanins have been
reported to exist as nanodomains of approximately ten
tetraspanins of a single type,57 therefore Tspan18 may
cluster Orai1 into pre-formed nanodomains, so modulat-
ing Orai1 lattice formation by STIM1. This may provide
a means by which endothelial cells fine-tune SOCE and
downstream functional responses.  It remains to be deter-
mined whether Tspan18 also regulates Orai2 and Orai3,
but we found no role for these Orai family members in
inflammatory mediator-induced HUVEC Ca2+ mobiliza-
tion, consistent with other studies.48,49
The inflammatory mediators thrombin and histamine
activate G protein-coupled receptors to induce down-
stream Ca2+ mobilization and the release of vWF from
Weibel-Palade bodies.14 Consistent with impaired Ca2+
signaling, Tspan18-knockout endothelial cells had
impaired inflammatory mediator-induced vWF release 
in vitro and in vivo. In contrast, basal release of vWF
appeared to be normal, because basal plasma vWF levels
were unaffected in Tspan18-knockout mice. We hypoth-
esize that impaired vWF release, in response to inflamma-
tory mediators, explains the in vivo phenotypes observed
in Tspan18-knockout mice. The protection from deep
vein thrombosis is consistent with the central role of vWF
in this disease.13 Furthermore, the reduced platelet depo-
sition in the microcirculation during myocardial
ischemia-reperfusion injury is consistent with the role of
vWF in this process.55,56  The hemostasis defect still needs
to be explained, because although a tail bleeding pheno-
type has been demonstrated in endothelial-specific vWF-
knockout mice, these animals also had low plasma
vWF,58,59 unlike Tspan18 knockouts. The tail bleeding
assay measures blood loss following excision of the tip of
the tail, which contains the two lateral veins, the dorsal
vein, and the ventral artery.  We speculate that endothe-
lial cells in the veins and artery, adjacent to the site of
excision, are activated and release vWF via Ca2+-depen-
dent signaling.  The vWF may trap platelets, facilitating
their aggregation and preventing excessive blood loss
from the site of tail injury.  Therefore, our data suggest
that acute release of vWF adjacent to a site of injury might
be important for hemostasis, at least for some types of
injury.  Finally, the lack of a phenotype in the two arterial
thrombosis models is consistent with the importance of
platelets in these models,38 and we found no defect in
aggregation in vitro for Tspan18-knockout platelets.
In summary, we have identified Tspan18 as a novel reg-
ulator of endothelial Orai1 and SOCE. Our in vivo data
show that Tspan18 regulates inflammation-induced vWF
release but not basal release, and promotes hemostasis
and thrombo-inflammatory processes but not arterial
thrombosis.
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